Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.6.1.1 (
adenylate cyclase
)
19,190
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The effect of GRF
adenylate cyclase
activation was studied in normal human, bovine and rat pituitary tissues. Human GRF (hGRF) activates
adenylate cyclase
in normal human pituitary membrane preparations in a concentration dependent manner (
ED5
0 = 10(-11) M). In bovine pituitary cells hGRF stimulates GH secretion into the medium (
ED5
0 = 7 X 10(-12) M) and activates
adenylate cyclase
(
ED5
0 = 10(-11) M). In normal rat pituitary cells in monolayer culture, rat GRF (rGRF) stimulates
adenylate cyclase
(
ED5
0 = 3 X 10(-11) M). In normal human pituitary membrane preparations and in normal rat pituitary cells in culture, somatostatin inhibits GRF-stimulated
adenylate cyclase
in a non-competitive manner, while it does not affect basal (i.e. non-stimulated)
adenylate cyclase
levels. VIP, a peptide which is structurally homologous to hGRF and rGRF is a weak GRF-agonist and activates
adenylate cyclase
in human and rat pituitary preparations at concentrations greater than 10 nM.
...
PMID:GRF is a highly potent activator of adenylate cyclase in the normal human, bovine and rat pituitary: interaction with somatostatin. 285 17
GH3 cells were used to study the effect of rat growth hormone-releasing factor on
adenylate cyclase
activity and its interaction with somatostatin. Rat GRF stimulates
adenylate cyclase
activity (
ED5
0 = 6 X 10(-8) M) and somatostatin-14 inhibits this GRF-stimulated activity in a non-competitive manner without affecting the basal enzyme levels. Inhibition by somatostatin-14 is observed at concentrations as low as 10(-11) M and the half-maximal effect is obtained with 10(-8) M. Somatostatin-28 is more potent than SS-14 and has an
ED5
0 of 3 X 10(-11) M. VIP is more active than rat GRF in stimulating
adenylate cyclase
activation. We conclude that in GH3 cells rat GRF behaves as a partial VIP agonist by interacting with VIP-preferring receptors and its effects are inhibited by somatostatin.
...
PMID:Somatostatin inhibits growth hormone-releasing factor-stimulated adenylate cyclase activity in GH, cells. 285 18